iTeos Therapeutics (ITOS)
(Delayed Data from NSDQ)
$16.16 USD
-0.05 (-0.31%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $16.15 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ITOS 16.16 -0.05(-0.31%)
Will ITOS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ITOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITOS
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade
ITOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?
Here's Why iTeos Therapeutics, Inc. (ITOS) Could be Great Choice for a Bottom Fisher
Wall Street Analysts Predict a 304.26% Upside in iTeos Therapeutics, Inc. (ITOS): Here's What You Should Know
Other News for ITOS
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
Noteworthy Friday Option Activity: ITOS, ROKU, C
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
iTeos Therapeutics, GSK initiate GALAXIES Lung-301 Phase 3 study
J.P. Morgan Remains a Buy on iTeos Therapeutics (ITOS)